Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review by Annika Smith, Aidin Karahasan, Deborah Yi, Sanjay Yapabandara, James Elhindi, Pablo Fernandez-Penas, Clara Chow, Sarah Zaman

Subjects: Get full text

Biological therapy in the reduction of cardiovascular risk in patients with psoriasis by Andrés Tirado-Sánchez

Subjects: “…Psoriasis. Biological therapy. Cardiovascular diseases. Proinflammatory cytokines.…”
Get full text

Epidemiology and Treatment Patterns of Fistulizing Crohn’s Disease in a Large, Real-World Australasian Cohort by Jack McNamara, William Wilson, Joseph L. Pipicella, Simon Ghaly, Jakob Begun, Ian C. Lawrance, Richard Gearry, Jane M. Andrews, Susan J. Connor

Subjects: Get full text

Role of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis by Milan Buc

“…Furthermore, we discuss how laboratory immunology can offer physicians its help in the diagnosis process and decisions what kind of biological therapy should be used.…”
Get full text

CMV Ileitis: To Treat or Not to Treat? Implications of Initiating Biologic Therapy for Concurrent Crohn’s Disease by Kendra T. Stilwell, Jason Estes, Maria T. Kurtz, James M. Francis, David T. Lynch, Anish A. Patel

“…When discovered concomitantly, there is no guidance in the current medical literature regarding the benefit of antiviral treatment of the CMV infection prior to initiating biologic therapy versus the risks of withholding treatment, as is currently recommended for nonimmunosuppressed individuals.…”
Get full text

Biological therapy for inflammatory bowel disease: cyclical rather than lifelong treatment? by Christian Philipp Selinger, Konstantina Rosiou, Marco V Lenti

“…Inflammatory bowel disease (IBD) treatment was revolutionised with the arrival of biological therapy two decades ago. There are now multiple biologics and increasingly novel small molecules licensed for the treatment of IBD. …”
Get full text

Analysis of periodontal status in Polish patients with rheumatoid arthritis treated with biological therapies by Joanna Samborska-Mazur, Dorota Sikorska, Marzena Liliana Wyganowska

Get full text

Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis by Andrew Thamboo, S. Kilty, I. Witterick, Y. Chan, C. J. Chin, A. Janjua, A. Javer, J. Lee, E. Monterio, B. Rotenberg, J. Scott, K. Smith, D. D. Sommer, L. Sowerby, M. Tewfik, E. Wright, M. Desrosiers

“…Abstract Background Recent evidence suggests that biologic therapy with targeted activity within the Type 2 inflammatory pathway can improve the clinical signs and symptoms of chronic rhinosinusitis with nasal polyposis (CRSwNP). …”
Get full text

Targeted dual biologic therapy for erythroderma of unknown etiology guided by high-parameter peripheral blood immunophenotyping by Hannah L. Cornman, Martin P. Alphonse, Arbor Dykema, Alexander L. Kollhoff, Kevin K. Lee, Jaya Manjunath, Emily Z Ma, Varsha Parthasarathy, Junwen Deng, Thomas Pritchard, Anusha Kambala, Melika Marani, Kayla A. Parr, Javid P. Mohammed, Madan M. Kwatra, Jay H. Bream, Won Jin Ho, Shawn G. Kwatra

Get full text

Effects of biologic therapy on novel indices of lung inhomogeneity in patients with severe type-2 high asthma by Nayia Petousi, Nick P Talbot, Ian Pavord, Peter A Robbins, Nicholas M J Smith, Graham Richmond, Asma Alamoudi, Lorenzo Petralia, Haopeng Xu, Dominic Sandhu, Grant AD Ritchie

“…Here, we assessed changes in lung inhomogeneity in patients with type-2 high asthma treated with biological therapy and explored the relationship between inhomogeneity measures and conventional asthma disease markers.Methods This was an observational study of 91 severe type-2 high asthma patients recruited from a tertiary asthma clinic, of whom 67 subsequently started anti-IL5 or anti-IL5R biologics. …”
Get full text

The role of intestinal ultrasound with colour Doppler in predicting the response to biologic therapy in inflammatory bowel disease patients by Mohamed Ali El-Nady, Nour Eldeen El-Hefny, Hayam Fathy, Wageeh Ali, Ahmed Mohammed Ashmawy

Get full text

Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy – a delphi methodology by Tiago Torres, Sofia Magina, Maria João Paiva Lopes

Subjects: Get full text

Clinical Implications for the Timely Diagnosis of Mycobacterium marinum in the Age of Biologic Therapy: A Case Report and Review of the Literature by Chris J. Lata, Kelle Edgar, Stephen Vaughan

Get full text

Ulcerative colitis: STRIDE-ing beyond symptoms with new standards by Shu Wen Tay, Kevin Kim Jun Teh, Tiing-Leong Ang, Malcolm Tan

Subjects: “…biologic therapy…”
Get full text

Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients by Federico Melograna, Padhmanand Sudhakar, Behnam Yousefi, Behnam Yousefi, Clara Caenepeel, Gwen Falony, Gwen Falony, Gwen Falony, Sara Vieira-Silva, Sara Vieira-Silva, Sara Vieira-Silva, Sreenikhitha Krishnamoorthy, David Fardo, Bram Verstockt, Bram Verstockt, Jeroen Raes, Jeroen Raes, Severine Vermeire, Severine Vermeire, Kristel Van Steen

Get full text

Relationship Between Patient Demographics and Biologic Therapy Use in Inflammatory Bowel Disease. A Single Center Cross‐Sectional Study by Mohammad Shehab, Abdulwahab Alsayegh, Munirah Alabdulhadi, Shahed Snober, Nouf Aleissa, Ahmad Alfadhli

“…ABSTRACT Introduction Biologic therapies treat patients with moderate to severe inflammatory bowel disease (IBD). …”
Get full text

Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials by Tyler Pitre, Daniel Lupas, Jasmine Mah, Matthew Stanbrook, Alina Blazer, Dena Zeraatkar, Terence Ho

“…However, in the subgroup of patients with blood eosinophils ≥300/mcL, both tezepelumab (MD 0.15 [95% CI 0.05 to 0.26]) and dupilumab (MD 0.13 [95% CI 0.06 to 0.19]) probably improved FEV1 above the MCID.Conclusion Dupilumab is effective at improving patient-relevant outcomes in COPD with higher eosinophil levels. Other biological therapies, including tezepelumab, have no important effect on patient-relevant outcomes.…”
Get full text

Reduction of depressive symptoms among patients with inflammatory bowel disease treated with biological therapy: a quantitative comparative incision study by J. Zinkevičiūtė, S. Ambrasas, A. Kiziela, R. Strumila, S. Brašiškienė, E. Dlugauskas

Get full text

A retrospective study on potential drug‒drug interactions in patients with severe asthma receiving biological therapy: a single-center experience by Mirna Momcilovic, Petra Turcic, Franka Butkovic, Sanja Popovic Grle

Subjects: Get full text

Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn’s disease by Haohang Su, Haohang Su, Shengwei Xiao, Zhiqing Liang, Zhiqing Liang, Tianrong Xun, Jinfang Zhang, Jinfang Zhang, Xixiao Yang, Xixiao Yang

Get full text